Actively Recruiting
Effects of 12-week n-3 PUFA Treatment (EPA) on Depressive Symptoms in Overweight/Obese Depressed Subjects With Low n-3 PUFA Status: Relationship With Systemic Inflammation
Led by National Science and Technology Council, Taiwan · Updated on 2026-02-27
50
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
N
National Science and Technology Council, Taiwan
Lead Sponsor
F
Fondation FondaMental
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are evaluating the effect of a 12-week treatment with n-3 polyunsaturated fatty acids (specifically eicosapentaenoic acid, EPA) on depressive symptoms in overweight or obese adults who have major depressive disorder and low omega-3 fatty acid status. This randomized, placebo-controlled trial also aims to explore how genetics, lifestyle, nutrition, and gut microbiota influence these effects in a Taiwanese cohort. Participants are randomly assigned to one of two groups: one receiving 2 grams per day of EPA through four capsules, and the other receiving a placebo at the same dosage and schedule. The treatment period lasts for 12 weeks, during which participants take their assigned capsules daily. During the study, depression severity is assessed at baseline and at weeks 2, 4, 8, and 12. Blood samples are collected at the start and end of the study to measure omega-3 levels. Additional assessments include stress, food intake, pleasure, and fatigue measurements at the same intervals. The trial monitors participants closely to evaluate changes in depressive symptoms and related factors over the treatment period.
CONDITIONS
Brief Title
NUTRIMOOD-Inflammation and Depressive Comorbidity in Obesity: Modulation by Omega-3 Polyunsaturated Fatty Acids Status
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with major depressive disorder
- Not currently taking antidepressant drugs
- Age between 18 and 54 years
You will not qualify if you...
- Diagnosis of schizophrenia
- Diagnosis of mania
- Diagnosis of anxiety disorders except social phobia and generalized anxiety
- Diagnosis of obsessive-compulsive disorder
- Diagnosis of post-traumatic stress disorder
- Alcohol or drug abuse or dependence except nicotine
- Active suicidal thoughts
- Serious medical or neurological conditions requiring corticosteroid, non-steroidal anti-inflammatory, immunosuppressive therapies, or chronic thyroid hormone replacement
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 12 weeks
Participants take either omega-3 fatty acid capsules or placebo daily to assess effects on depressive symptoms.
Visits at Weeks 0, 2, 4, 8, and 12 for assessments
Trial Site Locations
Total: 1 location
1
Mind Body Interface Research Center (MBI Lab & Care)
Taichung, Taichung, Taiwan, 404
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here